Leonard E Post
Insider (Form 4 reporting owner): Director CIK 1235862Name as filed: POST LEONARD EIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 28 Feb 2022, sold $1.9M in 27 sales (21 under a 10b5-1 plan set in advance) across 2 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| CG Oncology CGON | Director | 6 Dec 2024 | 16 Nov 2026 | – | 21$1.7M |
| uniQure QURE | Director | 28 Feb 2022 | 11 Jun 2026 | – | 6$160K |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | +0.9 pts19 trades, 53% above the sector | +51.9 pts15 trades, 67% above the sector | +97.7 pts15 trades, 87% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 9 | $1.2M | -$1.2M |
| 2025 | – | – | 12 | $580K | -$580K |
| 2024 | – | – | 3 | $75K | -$75K |
| 2023 | – | – | 2 | $51K | -$51K |
| 2022 | – | – | 1 | $13K | -$13K |
Every trade
27, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 16 Nov 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $92.00 | $92K | 10b5-1 plan | Form 4filed 17 Nov 2026 |
| 15 Oct 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $62.06 | $62K | 10b5-1 plan | Form 4filed 19 Oct 2026 |
| 15 Sep 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $72.98 | $73K | 10b5-1 plan | Form 4filed 17 Sep 2026 |
| 14 Aug 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $74.54 | $75K | 10b5-1 plan | Form 4filed 18 Aug 2026 |
| 15 Jul 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $71.17 | $71K | 10b5-1 plan | Form 4filed 17 Jul 2026 |
| 24 Jun 2026 | CG Oncology CGON | Sellafter exercising options | 5,000 | $70.00 | $350K | 10b5-1 plan | Form 4filed 25 Jun 2026 |
| 22 Jun 2026 | CG Oncology CGON | Sellafter exercising options | 5,000 | $65.00 | $325K | 10b5-1 plan | Form 4filed 23 Jun 2026 |
| 11 Jun 2026 | uniQure QURE | Sell | 1,993 | $27.06 | $54K | No | Form 4filed 12 Jun 2026 |
| 4 Jun 2026 | CG Oncology CGON | Sellafter exercising options | 1,000 | $54.50 | $54K | 10b5-1 plan | Form 4filed 5 Jun 2026 |
| 17 Nov 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $41.43 | $41K | 10b5-1 plan | Form 4filed 18 Nov 2025 |
| 13 Oct 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $43.25 | $43K | 10b5-1 plan | Form 4filed 15 Oct 2025 |
| 30 Sep 2025 | CG Oncology CGON | Sellafter exercising options | 5,000 | $40.09 | $200K | 10b5-1 plan | Form 4filed 1 Oct 2025 |
| 15 Sep 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $35.10 | $35K | 10b5-1 plan | Form 4filed 16 Sep 2025 |
| 3 Sep 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $28.00 | $28K | 10b5-1 plan | Form 4filed 4 Sep 2025 |
| 17 Jul 2025 | CG Oncology CGON | Sellafter exercising options | 2,000 | $28.00 | $56K | 10b5-1 plan | Form 4filed 18 Jul 2025 |
| 20 Jun 2025 | uniQure QURE | Sell | 2,112 | $14.45 | $31K | No | Form 4filed 24 Jun 2025 |
| 21 May 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $28.00 | $28K | 10b5-1 plan | Form 4filed 22 May 2025 |
| 28 Apr 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $30.76 | $31K | 10b5-1 plan | Form 4filed 29 Apr 2025 |
| 17 Mar 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $28.00 | $28K | 10b5-1 plan | Form 4filed 18 Mar 2025 |
| 18 Feb 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $28.61 | $29K | 10b5-1 plan | Form 4filed 19 Feb 2025 |
| 13 Jan 2025 | CG Oncology CGON | Sellafter exercising options | 1,000 | $29.66 | $30K | 10b5-1 plan | Form 4filed 14 Jan 2025 |
| 16 Dec 2024 | CG Oncology CGON | Sellafter exercising options | 1,000 | $28.84 | $29K | 10b5-1 plan | Form 4filed 17 Dec 2024 |
| 6 Dec 2024 | CG Oncology CGON | Sellafter exercising options | 1,000 | $34.55 | $35K | 10b5-1 plan | Form 4filed 6 Dec 2024 |
| 13 Jun 2024 | uniQure QURE | Sell | 2,222 | $5.14 | $11K | No | Form 4filed 18 Jun 2024 |
| 16 Jun 2023 | uniQure QURE | Sell | 2,291 | $18.83 | $43K | No | Form 4filed 20 Jun 2023 |
| 27 Feb 2023 | uniQure QURE | Sell | 389 | $19.73 | $8K | Not stated | Form 4filed 1 Mar 2023 |
| 28 Feb 2022 | uniQure QURE | Sell | 795 | $16.64 | $13K | Not stated | Form 4filed 2 Mar 2022 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.